BPC-157 vs TB-500: Side-by-Side Research Compound Profiles

Among peptide research compounds that appear frequently in published in-vitro and animal-model literature, BPC-157 and TB-500 are two of the most studied. Though they are sometimes grouped together in research discussions, their molecular origins, mechanisms of action, and the body of literature surrounding each are distinctly different. This post provides a structured comparison for qualified researchers evaluating these compounds for in-vitro research use only.

All compounds discussed are sold for in-vitro research use only by qualified researchers. Not for human consumption.

What Is BPC-157?

BPC-157 — Body Protection Compound-157 — is a synthetic pentadecapeptide (15 amino acids) with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was originally isolated and characterized from human gastric juice. Its CAS registry number is 137525-51-0.

BPC-157 is not naturally occurring in isolation in meaningful concentrations; the research compound is fully synthetic, produced through solid-phase peptide synthesis (SPPS). Its stability profile is notable in research contexts: unlike many peptides, it shows relative resistance to degradation in aqueous environments, which has made it a practical subject for a range of in-vitro assay conditions.

BPC-157 Mechanism of Action in the Research Literature

Published research characterizes BPC-157 as a modulator of multiple growth factor pathways. Specifically, studies have examined its interaction with the vascular endothelial growth factor (VEGF) pathway and its apparent influence on nitric oxide (NO) signaling systems. In-vitro and rodent-model literature has investigated its effects on angiogenic signaling in cell culture models (Seiwerth et al., 2018, Current Pharmaceutical Design), modulation of the dopaminergic system in animal models, cytoprotective effects in gastric mucosal cell lines, and interaction with the growth hormone receptor pathway in rodent models.

A key feature noted across multiple in-vitro studies is BPC-157’s apparent pleiotropic profile — meaning its documented interactions span more than one signaling pathway rather than a single receptor target. Researchers should consult primary literature for full methodological context before designing BPC-157 in-vitro experiments.

What Is TB-500?

TB-500 is the common research designation for a synthetic peptide derived from Thymosin Beta-4 (Tβ4), specifically the fragment corresponding to amino acids 17–23 of the full Tβ4 sequence (Ac-LKKTETQ). Its CAS registry number is 77591-33-4. TB-500 is not identical to full-length Thymosin Beta-4; it is a shorter fragment that is studied because of its proposed role in the actin-binding activity attributed to the parent molecule.

Thymosin Beta-4 is an endogenously occurring protein involved in actin sequestration — specifically, binding G-actin (monomeric actin) and modulating the ratio of free actin available for polymerization. The Ac-SDKP sequence within TB-500 has been studied extensively in the context of actin dynamics research.

TB-500 Mechanism of Action in the Research Literature

The primary mechanistic focus in TB-500 research is its relationship to actin regulation. Thymosin Beta-4 and its fragments have been characterized as G-actin sequestering proteins, inhibiting actin polymerization by binding monomeric actin. Published research has explored actin-binding kinetics of the Tβ4 fragment in cell-free assay systems (Goldstein et al., 2005, Annals of the New York Academy of Sciences), effects on cell migration in scratch assay models, interaction with integrin-linked kinase (ILK) signaling in in-vitro models, and cardioprotective signaling pathways in rodent cardiac cell models (Bock-Marquette et al., 2004, Nature).

The actin-centric mechanism of TB-500 makes it mechanistically distinct from BPC-157’s growth factor pathway interactions. This distinction is important for researchers designing assays — the two compounds are not interchangeable research tools, and their selection should follow the specific pathway or model being studied.

Key Mechanistic Differences: BPC-157 vs TB-500

Property	BPC-157	TB-500
CAS Number	137525-51-0	77591-33-4
Amino Acid Length	15 (pentadecapeptide)	7 (heptapeptide fragment)
Origin	Derived from gastric juice characterization; fully synthetic	Synthetic fragment of endogenous Thymosin Beta-4
Primary Mechanism (Literature)	Growth factor pathway modulation (VEGF, NO systems)	Actin sequestration; cytoskeletal dynamics
Key Research Models	Gastric mucosal, angiogenic, neurological cell models	Cell migration assays, cardiac cell models, in-vitro actin assays

Published Literature: Research Use Cases by Compound

Both compounds have accumulated bodies of peer-reviewed research, primarily in in-vitro systems and rodent models. Neither compound has been approved for any clinical application, and all findings referenced here are from preclinical research contexts.

For BPC-157, the most-cited research applications include gastric mucosal cytoprotection models, angiogenesis assays using HUVEC (human umbilical vein endothelial cell) cultures, and dopamine receptor interaction studies in rodent nervous system models.

For TB-500, the most active research domains include actin dynamics in cell migration studies, cardiomyocyte protection studies in vitro, and hair follicle stem cell activation models (Philp et al., 2004, Journal of Cell Science).

Using BPC-157 and TB-500 Together in Research

Some researchers working across multiple pathway models choose to include both compounds in their procurement. Cre8tive Labs offers a pre-formulated combination research blend — the GLOW Blend — which contains BPC-157 (10mg), TB-500 (10mg), and GHK-Cu (50mg) in a single research vial. This blend is available for in-vitro research use only and is intended for qualified researchers studying multiple overlapping pathways simultaneously.

Sourcing Considerations: COA Verification for Each Compound

Because BPC-157 and TB-500 are both synthesized peptides sold in the unregulated research supply market, sourcing quality varies significantly between vendors. For each compound individually, researchers should verify HPLC purity ≥98% with a publicly shareable chromatogram, LC-MS identity confirmation matched to the correct molecular weight (BPC-157: ~1419.5 Da; TB-500: ~887.0 Da), endotoxin (LAL) results within acceptable thresholds for cell-based assay work, batch/lot number traceable to a specific production run, and third-party COA-tested documentation from an independent lab with public verification.

Cre8tive Labs publishes third-party COA-tested results for all peptide research compounds, including BPC-157 and TB-500, with QR-code verified links to independent analytical records.

Browse research compounds at /shop/ and review COA documentation at /coa/.

All Cre8tive Labs products are sold for in-vitro research use only by qualified researchers. Third-party COA-tested. Not for human consumption.

Disclaimer: All content is for informational and educational purposes only. Cre8tive Labs products are sold for in-vitro research use only by qualified researchers. Not for human consumption.